A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients with Bronchiolitis Obliterans syndrome (BOS) after Allogeneic Hematopoietic Cell Transplant (HCT)
MD Anderson Study Status
Itacitinib, Itacitinib Adipate
This phase I trial studies how well itacitinib works for the treatment of bronchiolitis obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Stem Cell Transplantation
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.